CIIP Singapore -PEGASUS-BPE-CAR-T: Cell and gene therapy manufacturing faces major bottlenecks due to low-yield, high-cost, and difficult-to-scale plasmid DNA systems that limit efficient viral produc...
Pegasus Biotech Incorporated
9 enregistrements totalisant 1,881,545.00 $ CAN, selon les données ouvertes officielles du gouvernement du Canada.
Intégrer ce graphique
Par ministère
| Conseil national de recherches Canada | $1,878,323 | 8 enregistrements |
| Affaires mondiales Canada | $3,222 | 1 enregistrement |
Enregistrements
This project leverages the combined vaccine development platform technologies of Pegasus Biotech, ConserV Bio and 4BaseBio to evaluate and enhance the manufacturing capability of a novel Canadian plas...
The BPE technology is a novel, DNA plasmid backbone/production method that is ultra-low-cost, and has superior transfection efficiency. The technology has been demonstrated at lab scale (1.0 L fermen...
Pegasus Biotech is developing the process and analytical methods to commercialize the BPE plasmid technology as a DNA plasmid production platform.
This International Co-Innovation Action Program (ICAP) project will prepare the Firm to enter into future international co-innovation work.
Pegasus Biotech is developing a DNA vaccine development platform to provide accelerated vaccine development services to new and existing clients.
The Project will support development of intellectual property capacity within the Firm.
Participation in the Canadian medical biotechnology co-innovation mission to the Eureka Global Innovation Summit and Swiss Biotech Day in Switzerland – May 3 to 8, 2026. Delegation led by the National...
The purpose of the Canadian International Innovation Program (CIIP) contribution agreement is to support Canadian SMEs identify international partners in CIIP target countries for industrial research...